Dianthus Therapeutics
DNTH
95 hedge funds and large institutions have $766M invested in Dianthus Therapeutics in 2024 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 41 increasing their positions, 24 reducing their positions, and 12 closing their positions.
211% more capital inflows, than outflows
Capital inflows: $142M | Capital outflows: $45.7M
71% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 24
33% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 12
4% more funds holding
Funds holding: 91 → 95 (+4)
2.48% more ownership
Funds ownership: 106.86% → 109.34% (+2.5%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
31% less call options, than puts
Call options by funds: $9K | Put options by funds: $13K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCG Crossover Management
Palo Alto,
California
|
+$38.6M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
+$18.3M |
| 3 |
Vestal Point Capital
New York
|
+$17.5M |
| 4 |
OCA
Octagon Capital Advisors
New York
|
+$9.35M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$9.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA Capital Management
Boston,
Massachusetts
|
-$12M |
| 2 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$8.32M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$6.28M |
| 4 |
5VM
5AM Venture Management
San Francisco,
California
|
-$5.24M |
| 5 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$2.6M |
DNTH Hedge Fund Activity: Q4 2024 in Review
95 of the 7,614 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q4 2024, worth a combined $766M — down 11% from $859M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new DNTH positions and 12 closed out — a net gain of 4 holders — while 41 added to existing stakes and 24 trimmed.
The largest buyer was TCG Crossover Management, opening a new position worth an estimated $38.6M. The largest seller was RA Capital Management, cutting an estimated $12M.
- 95 institutional investors held Dianthus Therapeutics (DNTH) as of Q4 2024, up from 91 in Q3 2024.
- Funds reported $766M of Dianthus Therapeutics stock for Q4 2024, down 11% quarter-over-quarter.
- 16 funds opened new Dianthus Therapeutics positions in Q4 2024 and 12 closed out, a net change of +4 holders.
- The largest Dianthus Therapeutics buyer in Q4 2024 was TCG Crossover Management, an estimated $38.6M added.
- The largest Dianthus Therapeutics seller in Q4 2024 was RA Capital Management, an estimated $12M sold.
Based on aggregated 13F filings for Q4 2024.